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Essential hypertension is the most common primary diagnosis in the US, with myriad and 
serious sequelae inflicting significant morbidity upon individuals and economic losses 
upon society.  Estimates of adherence to prescribed medication regimens range from 20% 
to 60%.  Because hypertension is largely asymptomatic, patients may underestimate both 
the benefits of adherence and the costs of nonadherence.  This novel educational 
intervention seeks to encourage adherent behavior by providing patients with a conscious 
manifestation of their disease severity through manipulation of pressurized balls. 
 
Methods 
Randomized controlled pilot trial of patients under treatment for hypertension with SBP 
≥140mmHg or DBP ≥90mmHg at index visit, selected by convenience sample at a VA 
Primary Care Clinic.  Baseline clinical, demographic, medication taking habits and 
motivation data obtained by surveys and chart abstraction.  All subjects received a short 
talk on the dangers of hypertension.  Intervention Group subjects simultaneously 
squeezed rubber balls in each hand filled to air pressures differing by the same amount 
that their current SBP exceeded 120mmHg.  Followup medication taking habits, 
motivation, medication possession ratios and blood pressure measurements were 
determined by telephone survey, pharmacy and clinical records over 90-, 180-, 270- and 
360-day time periods.  Feasibility of a larger study was determined by structured 
interviews with a physician and nurse who employed the intervention in clinical practice. 
 
Results 
Thirty subjects were enrolled into Intervention and Control Groups of equal size.  
Immediate motivational impact by 7-point scale significantly favored the Intervention 
(6.3, p < 0.001 vs 4.3, p = 0.164).  Change in self-reported adherence on an 8-point scale 
at 90-days favored the Intervention but was not significant (0.5, p = 0.372 vs -0.1, p = 
0.798).  Change in 360-day medication possession ratio favored the Intervention and 
approached significance (11.3%, p = 0.088 vs 0.7%, p = 0.934).  Both Groups 
demonstrated clinically relevant improvements in MAP with greater magnitude, duration 
and significance for the Intervention Group through 360 days (-12.2mmHg, p = 0.008 vs  
-6.0mmHg, p = 0.164).  Larger improvements in adherence were significantly associated 
with greater baseline motivation and immediate motivational impact from the 
intervention while longer disease experiences were associated with less improvement.  
Clinicians reported favorable reception from their patients and felt that the intervention 
represented a simple and helpful tool that they would use in everyday practice.  
 
Conclusions 
The results of this pilot trial suggest that a novel, brief educational intervention designed 
to provide a somatosensory manifestation of an otherwise asymptomatic disease process 
may show promise in promoting adherent behavior and clinically useful reductions in 
blood pressure in patients with poorly controlled hypertension.  A larger study appears 
feasible and is required to confirm and investigate the statistical significance of these 
results. 
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Essential hypertension is the most common primary diagnosis in the United States (1).  
Defined in adults as a systolic blood pressure (SBP) greater than 140mmHg or diastolic 
(DBP) of greater than 90mmHg, high blood pressure has been linked to a myriad of 
disorders including stroke, heart disease, renal disease, ocular disease and aortic 
dissection.  More than sixty-five million Americans have blood pressure high enough to 
warrant treatment (2-4).  Worldwide estimates of hypertension prevalence approach one 
billion individuals resulting in 7.1 million deaths annually.  The World Health 
Organization estimates that 62% of cerebrovascular disease and 49% of ischemic heart 
disease are sequelae of high blood pressure (5, 6).  Other studies find that death from 
ischemic heart disease, kidney disease and stroke increases progressively and linearly 
with severity of hypertension (7, 8).  The Framingham Heart Study found that 
normotensive sixty-five year olds who live to eighty-five have a 90% chance of 
becoming hypertensive in the intervening years (9).  Economists estimate that the costs of 
hypertension in the United States alone exceed $100 billion annually (10). 
 
The insidious and insensible nature of hypertension makes the disease easy for the patient 
to miss, minimize or deny.  Approximately 30% of hypertensive adults are unaware of 
their condition.  More than 40% of hypertensive individuals are not under treatment and 
an estimated 53% of patients do not have their SBP controlled to less than 140mmHg 
(11).  The efficacy of antihypertensive medicines in reducing blood pressure and the 
incidence of clinical sequelae when taken appropriately is well documented (12, 13).  
Failure to attain recommended targets can be due to many different phenomena including 
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poor adherence to hypertensive medication and prescribed medical regimes, a problem 
which is particularly prevalent in asymptomatic and chronic diseases (14, 15).  Of those 
who are under treatment, estimates of adherence with antihypertensive medical regimes 
range from 20 to 60% (16-21).  Recommendations regarding lifestyle modification are 
even less likely to be followed with estimates of adherence ranging from 20% to 30% 
(22). An estimated 15% of nonelective hospital admissions are due to poor medical 
adherence (23) and the US Chamber of Commerce estimates the cost of poor 
antihypertensive medical adherence at $13 to 15 billion per year (24). Thus, effective 
approaches to improve adherence have the potential to significantly affect morbidity and 
mortality in patients and decrease health care costs.   
 
“Adherence” and “compliance” are synonyms, classically defined as the extent to which 
a patient’s behaviors coincide with health care providers’ recommendations for health 
and medical advice (25).  Recently, medical practitioners and researchers have shifted 
away from use of compliance, in favor of adherence in order to better recognize the 
patient’s responsibility, agency and involvement in therapeutic decisions and encompass 
their ability and willingness to abide by a prescribed therapeutic regimen (26).  
Nonadherence is typically characterized as purposeful or incidental.  Purposeful 
nonadherence refers to willful departure from the recommendations of the physician, for 
example “I just don’t think I need medication.”  Incidental nonadherence involves 
unintentional and nonsystematic departures from the prescribed treatment plan, for 
example “I ran out of/lost my pills” (15, 27).  Forgetfulness and discomfort with side 
effects are consistently found to be the most prevalent explanation for incidental and 
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purposeful antihypertensive nonadherence respectively (18, 28, 29).  Estimates of these 
components’ contributions to aggregate nonadherence vary, but one study’s findings of 
42% incidental and 15% purposeful are representative of values commonly found in the 
literature (15).  Poor adherence manifests along a spectrum: the patient may fail to take 
any medication, may discontinue prematurely or may take medication in a manner that 
deviates from the prescription (30). 
 
A significant body of work evaluates factors associated with poor adherence.  Certain 
demographic and clinical variables have been shown to be inconsistently associated with 
compliance levels: age, gender, race, education, employment status, socio-economic 
status, presence or absence of symptoms, quality of followup, complexity and duration of 
regimen, side effects and certain comorbidities (15, 31-34).  In addition, investigators 
have examined the impact of financial, psychosocial and behavioral factors such as cost 
of medication, level of insight into illness, belief in the benefit of treatment, fear of 
dependence on drugs, fear or intolerance of side effects, religious beliefs, knowledge 
about hypertension, support networks, quality of therapeutic alliance, access to and 
satisfaction with the healthcare system, depression, internal versus external perceived loci 
of control and alcohol use (35-39).   
 
In fact, when a patient weighs their personal experience with a drug’s beneficial and 
deleterious effects, costs and their understanding of the risks associated with 
nonadherence, it may seem rational to forgo their medication (14, 40).  Studies have 
found that nonadherent patients are usually able to justify their actions through rational 
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arguments that take into account their symptoms, side-effects and personal circumstances 
(29).  The fact that these arguments are often predicated on misunderstanding of a drug’s 
purpose, side effects or symptomatic target does not lessen their weight in the decision 
making process.  This rationalist approach is given an analytic framework in the Health 
Belief Model (HBM) which posits that people seek to avoid illness if the treatment is 
perceived to be less deleterious than the illness itself as assessed along four core beliefs: 
1) motivation - degree of interest in and concern about their health; 2) susceptibility - 
perceptions of vulnerability to sequelae; 3) severity - perceptions concerning the 
seriousness of the consequences of nonadherence and; 4) benefits and costs - evaluation 
of the treatment’s efficacy balanced against barriers such as cost and side effects (41).  In 
the words of one patient, “I mean, it seems to me that like everything else it was a 
question of balancing the risks.  You always have risks if you have long term medication 
because in a sense you become dependent on it, but on the other hand if you don’t take 
them, then you risk... heart problems and strokes and all the other things which happen as 
a result of high blood pressure” (42).  In the HBM framework, the decision to forego the 
prescribed therapy is simply the result of the patient’s personal weighting of these often 
nebulous factors. 
 
This weighting process emphasizes the importance of sufficient understanding of illness 
in forming an accurate assessment of the severity of the disease and costs of 
nonadherence such that they are not underestimated.  Lack of knowledge of the 
symptoms (or lack thereof), basic pathophysiology and treatment regarding disease 
compromises the adherence decision and thus the success of outpatient therapy (43).  In 
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this regard, hypertension presents a particular challenge because the cues of pain and 
discomfort that normally prompt people to seek and follow the advice of a medical 
professional are absent.  In addition, medical treatments for hypertension lack the 
negative reinforcement of conscious symptom alleviation that can help drive adherence 
for other maladies.  As a result, treatment is encouraged through appeals to abstract 
health advantages, long-term benefits and decreased risk of future disease (29).  Both the 
risks of nonadherence and the benefits of treatment are remote and abstract while the side 
effects and cost of medication are quite real and concrete.  Studies comparing beta-
blockers prescribed for angina and hypertension found significantly lower adherence 
rates for hypertension despite the fact that both diseases are associated with substantial 
cardiac morbidity (44, 45).  Other studies concluded that patients who perceive 
hypertension as a symptomatic disease have higher rates of medical adherence (15). 
 
Patient motivation also plays a role in adherence behavior and is interwoven with the 
concepts of knowledge of costs and benefits of treatment and disease insight.  One 
widely-studied framework of motivation and competence, Self-Determination Theory 
(SDT), posits that different kinds of motivation underlie health behaviors and thus 
outcomes and exist along a continuum of autonomy (46). Autonomous, self-derived 
forms of motivation (e.g. “I take my hypertension pills because I believe it is the best 
thing for my health”) are associated with positive health behaviors including medical 
adherence.  Interventions shown to increase autonomous forms of motivation are 
associated with better health outcomes (47-49).  In contrast, “controlled” or externally 
derived motivations (e.g. “I take my hypertension pills because others would be upset 
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with me if I didn’t”) are linked to poorer adherence and well-being (50).  Because 
autonomy and agency are key to successful behavioral change, SDT further proposes that 
health interventions require a process of proactive internalization in which people take in 
and integrate the motivations and competencies initially reinforced by an external source 
(e.g. physician, family members or the media) (46, 47).  This process of internalization 
opens up opportunities for interventions seeking to improve the health behaviors of the 
poorly adherent hypertensive patient. 
 
Given the diversity of barriers to adherence, it is unsurprising that an optimal intervention 
for its improvement remains elusive.  Scholars have produced more than fifty well-
designed RCTs exploring methods to increase antihypertensive adherence rates (51).  
These studies can be broadly categorized into four approaches: 1) patient education, 2) 
simplification of dosing regimens, 3) patient motivation, support and reminders and, 4) 
complex initiatives including more than one of these approaches.  These interventions 
employ diverse modalities including: lecture, interactive and programmed instruction 
sessions (52-55), worksite access to medical advice (56, 57), self-monitoring of blood 
pressure (54, 56, 58), psychological counseling (49), reward systems (56, 58), home visits 
or phone calls from care providers or researchers (53, 59, 60), and special reminder 
medicine packaging (43) among many others.  Design and implementation of 
antihypertensive intervention studies are highly heterogeneous and their efficacy varies 
widely.  For example, dose simplification studies have resulted in relative improvements 
of 8% (61) to 19.6% (62) as measured by pill count and electronic monitoring 
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respectively.  Studies of behavioral interventions cite improvements from 5% (53) to 
12% (63) by self-report and pill count. 
 
Studies of the effects of educational efforts regarding hypertension’s dangers, progression 
and sequelae on adherence have produced mixed results.  Some investigators have found 
that the predictive value of higher levels of disease knowledge is strongest with short-
term rather than long-term treatments (64).  Several studies find that frequent blood 
pressure monitoring (a form of recurrent information as to disease severity) is associated 
with both adherence and with return to a drug regimen for nonadherent patients (23, 65).  
Researchers have found that for patients with chronic conditions, the adherence levels of 
newly diagnosed patients were more likely to respond positively to educational efforts 
than those with longer disease experiences (66).  Often, educational efforts must 
challenge well-entrenched beliefs that are at odds with the diagnosis, for example “I can’t 
have hypertension because I don’t feel stressed”, or “I can’t be sick because I don’t feel 
sick” (67, 68).   
 
Meta-analyses have identified intervention types that appear to have a “significant” (but 
widely varying) impact on increasing patient adherence and improving clinical outcomes 
(69-73).  Although not amounting to a consensus among researchers, several reviews cite 
improvements following multi-approach, patient-specific interventions (69, 71, 72, 74). 
Researchers have repeatedly found that successful interventions typically involve 
longitudinal application of combinations of approaches and modalities.  For example, in 
an analysis of 16 educational interventions using indirect adherence metrics, the average 
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effect size almost doubled when a behavioral component was added (71).  Unfortunately, 
multi-approach and longitudinal, multi-contact initiatives tend to be complex, time 
consuming and expensive.  As a result, reviewers cite the need for work on simpler, more 
cost-effective interventions capable of being efficiently integrated into routine clinical 
practice (75). 
 
The Medical Research Council has provided guidance stressing the importance of pilot 
work to refine the design of adherence interventions prior to embarking on a definitive 
trial (76).  As such, the aim of this project is to address the utility and feasibility of a full 
scale study to add a simple, brief, patient-specific somatosensory component to the 
experience of hypertension, a disease where conscious sensory feedback is otherwise 
unavailable.  Searches of the literature (PubMed.org on December 12, 2012) and patent 
filings (patft.uspto.gov on December 15, 2012) identified no similar device for the 
education of hypertensive patients and no documentation of a similar intervention.  
Review of 618 manuscript titles returned for the following searches of the PubMed 
Database resulted in no similar inquiries: somatosensory AND intervention; 
somatosensory AND intervention AND hypertension; conscious AND intervention AND 
hypertension; *symptomatic AND intervention AND hypertension. 
 
The contemplated intervention may provide a novel, fast, safe, inexpensive and easily 
performed opportunity to educate patients during the office visit with inexpensively 
fabricated equipment.  Providing immediacy, tangibility and urgency to the patient’s 
condition - with feedback specifically calibrated to their degree of illness in the moment - 
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may give impetus to greater levels of medical adherence through better understanding of 
disease severity and increased levels of autonomous motivation.  In keeping with the 
recommendations of prior adherence improvement trials, the current inquiry implemented 
a combination of previously studied metrics to capture the effects of the proposed 
intervention on antihypertensive adherence (18, 30, 74). 
 
Hypothesis 
Patients with poorly controlled essential hypertension who simultaneously and repeatedly 
squeeze two rubber bladders, inflated to pressures differing by the same amount that the 
patient’s current systolic blood pressure exceeds its ideal level, will exhibit better 
adherence to anti-hypertensive medication regimes than patients who receive no such 
intervention as measured by self-report at index session and 90-day followup. 
 
Aims 
Demonstrate utility of a full-scale study through exploration of any effect on the primary 
outcome of self-reported medical adherence and secondary outcomes including change in 
medication possession ratios, blood pressure and motivation.   
 
Demonstrate feasibility of a full-scale study through implementation of control and 
intervention sessions, as well as interviews with clinicians who enrolled patients and 





This randomized, controlled pilot study tested a five minute in-office intervention 
consisting of a tactile, patient-specific representation of high blood pressure in a sample 
of patients with poorly controlled essential hypertension.  The intervention was 
performed using a device conceived, designed and fabricated by the co-investigator.  
Approval for the study was granted by the Human Subjects Subcommittee (HSS/IRB) of 
the Veterans’ Affairs Connecticut Healthcare System of West Haven (VACT) and the 
Human Investigation Committee (HIC) of the Yale School of Medicine.  The study was 
performed under the supervision of an Associate Professor of Internal Medicine who is 
an attending physician in the Clinic and served as Principal Investigator. 
 
Inclusion and exclusion criteria 
Eligible patients included any patient over eighteen years old treated at the VACT 
Primary Care Clinic between June 15, 2010 and August 15, 2010 with diagnosis of 
essential hypertension by ICD-9 in the patient’s Problem List and SBP at check-in of 
≥140mmHg or DBP of ≥90mmHg and an active prescription for medications from the 
following classes: diuretics, beta blockers, ACE inhibitors, angiotensin II receptor 
blockers, calcium channel blockers, alpha blockers, combined alpha and beta blockers, 
central agonists, peripheral adrenergic inhibitors, vasodilators and sympathetic inhibitors.  




Ineligible patients included those under eighteen years old, no diagnosis of essential 
hypertension prior to index session, no home address or phone, pregnant, incompetent to 
consent, non-English speaking, unable to perform the intervention, unable or not 
expecting to attend followup appointment, and those with any comorbidities that would 
raise the risk or pain associated with the mild physical exertion necessary to perform the 
intervention: history of myocardial infarction, history of stroke, history of congestive 
heart failure, on supplementary oxygen, upper extremity arthritis, upper extremity 
vascular compromise, or recent upper extremity surgery.  Patients were also excluded if 
the care provider felt that the patient should not participate for any reason.  Exclusion of 
patients with history of advanced vascular compromise or atherosclerotic disease was 




The co-investigator received $5,244 from a National Institutes of Health NHLBI 
Research Fellowship.  
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Preliminary results were reported at the AMA Medical Student Research Symposium in 
2010. 
 
Recruitment and setting 
Investigators recruited a convenience sample of patients presenting for regularly 
scheduled or acute primary care visits at the VACT Primary Care Clinic from June 15 
through August 15, 2010. 
 
Every morning, a clinical room and a roster of the day’s patients were made available to 
the co-investigator.  The co-investigator pre-screened patients with diagnoses of essential 
hypertension and active prescriptions for antihypertensive medication via chart review 
using the VA Computerized Patient Record System (CPRS).  Prior to being seen by their 
physician, all patients underwent evaluation by a staff healthcare provider including 
assessment of vital signs.  If the SBP recorded at check-in was ≥140mmHg or DBP 
≥90mmHg and no exclusions were present, the co-investigator placed a note in the 
patient’s file indicating that they appeared to qualify for the study and asking the treating 
physician to discuss study participation if time permitted.  If the patient indicated interest, 
the caretaker introduced the patient to the co-investigator at the conclusion of the primary 
care visit.  The co-investigator then confirmed that the inclusion and exclusion criteria 
were met.  Subjects then participated in the informed consent process as guided by the 




Upon completion of the consent process and after any questions were addressed, the 
subjects were randomized and assigned to one of two Groups - Intervention or Control - 
according to a pregenerated list of 0’s and 1’s using the Excel =RAND() function.  For 
practical reasons, the co-investigator could not be blinded to Group assignment as they 
delivered the intervention and also collected, entered and analyzed the data.  Moreover, 




All patients from both Groups underwent the same session at index visit including filling 
out surveys, listening to an educational script on the dangers of uncontrolled hypertension 
and followup as outlined below.  The Intervention Group received the somatosensory 
pressure demonstration during the index visit whereas the Control Group did not. 
 
Demographic questionnaire and baseline clinical data 
Subjects from both the Control and Intervention Groups underwent a short investigator-
administered demographic survey including questions on age, gender, race and marital 
status.  Subjects were also asked to provide contact information (address and telephone 
number) for followup.  Additional patient profile data were later abstracted from the chart 
including date of hypertension diagnosis, comorbidities, number of medications and 
number of antihypertensive medications.  The number of index hypertension medications 
was calculated by taking the average number of active scripts for the 30 days preceding 
the index visit. 
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Motivation and adherence habits questionnaires 
Subjects were then prompted to complete a series of Likert-scale and yes/no questions to 
the best of their ability.  Research staff left the room for 5 minutes; if subjects required 
any clarification, it was given by the co-investigator before proceeding to the next stage 
of the session.  Self-administration of the questionnaires was intended to reduce observer 
bias. 
 
Subjects first completed the Treatment Self-Regulation Questionnaire (TSRQ) (Image 1, 
left), a twelve-item questionnaire designed to assess baseline motivation levels.  The 
TSRQ is a theoretically derived scale that assesses the degree and origin of motivation 
possessed by patients contemplating medical treatment or healthy behavior.  The 
questionnaire was developed by the NIH Behavioral Change Consortium (77, 78) and has 
been widely employed to gauge “controlled” and “autonomous” or “internal” motivation.  
It has been validated across several settings and health behaviors (50, 79-83).  The 
wording of the generic questionnaire was modified to provide relevance to 
antihypertensive medical adherence.  Subjects used a 7-point Likert scale to rate their 
agreement with each item describing the reasons they would take their hypertension 
medications as prescribed to them (1 = not true at all, 7 = very true) for a total possible 
score of 84 evenly divided between autonomous and controlled metrics. 
 
Prior studies have found that autonomous motivation in initiating behaviors is associated 
with greater sense of perceived competence in carrying out those behaviors and with 
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positive health behaviors including adherence to medication regimens (48, 83, 84).  One 
study of HIV antiretroviral adherence found autonomous components of the TSRQ 
associated with better dose timing but not with dose adherence (84).  Another inquiry 
concluded that positive changes in autonomous motivation were found to predict 
improvement in glycemic control for patients with chronic diabetes (48). 
 
Questions 1-6 of the TSRQ relate to autonomous forms of motivation in which behavior 
finds its antecedents in volition and choice.  Questions 1-3 focus on “identification” 
wherein behavior is positively endorsed and valued by the individual.  Questions 4-6 
relate to “integration” in which a behavior is perceived as being part of the larger self and 
connected to broader values and goals. 
 
Questions 7-12 consider controlled types of motivation.  Items 7 and 8 explore 
“introjected” regulation in which behaviors are performed to avoid feelings of guilt.  
Questions 9-12 consider “external” motivation which drives behaviors performed in order 
to obtain a reward or to avoid negative consequences (50, 64). 
 
Subjects were then prompted to complete the Morisky Medication Adherence Scale 
(MMAS) (Image 1, right), an eight-item questionnaire designed to assess baseline 
adherence levels (85).  The questionnaire was recently developed as an improvement 
upon a widely used four-item assessment (86) and has been shown to have a strong, 
graded and statistically significantly association with anti-hypertensive medical 
adherence as measured by electronic Medication Event Monitoring System (MEMS) and 
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pharmacy refill records (87).  These studies also confirm the predictive validity of the 
MMAS for adequate blood pressure control (85, 87). 
 
Each of the eight items measures a specific medication taking behavior and not a 
determinant of adherence such as motivation.  Each question is scored 1 for “no” and 0 
for “yes” with the exception of question 5 which is reverse coded and question 8 which 
uses a 5-point Likert scale and is coded fractionally.  Aggregate scores for the MMAS are 
typically segregated into three levels of adherence: a perfect score of 8 corresponds to 
“high” adherence, 6 to < 8 indicates “medium” adherence, and a score of < 6  is 
associated with “low” adherence.  The primary validation study for the MMAS found that 
67.2% of low adherers had uncontrolled blood pressure compared to 55.2% and 43.3% of 
medium and high adherers respectively.  The same study found that scores of 6 or greater 
had 93% sensitivity and 53% specificity for adequately controlled blood pressure (85).  
 
The use of questionnaires was thought to provide a compromise between simpler but less 
reliable assessments such as interviews and more complex or invasive methods that may 
be more accurate (22, 88, 89).  Although easy and cheap, interviews are subject to 
distortion due to socially desirable answers, approval-seeking, variable interviewer 
experience, phrasing and interpersonal dynamics.  Self-administered questionnaires have 
the advantages of prior validation, ease of administration and the possibility of providing 
explanations for adherence behavior (as opposed to pharmacy data).  Disadvantages of 
this approach include discontinuity of the data and the fact that the accuracy of the results 
depend on the instrument chosen (30).  MMAS questions are phrased in the negative to 
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counter the tendency of patients to respond to questions in healthcare settings in the 
affirmative (89). 
 
Although considered the gold standard for indirect adherence measurement, electronic 
monitoring of pill usage via MEMS (30) was not practical due to cost.  Direct measures 
of adherence such as blood tests for drug or metabolite levels, biological markers or 
direct observation of the subject receiving medications were not feasible with the 
resources available to the investigators and are subject to their own disadvantages (90).   
 





Informational script - the importance of BP management 
For each item, please circle the number from 1 to 7 that best expresses your beliefs: 
 
1. I take my high blood pressure medications because it is very important for being 
as healthy as possible. 
Not true 
at all 1 2 3 4 5 6 7 
Very 
true 
2. I take my high blood pressure medications because it is the best thing for my 
health. 
Not true 
at all 1 2 3 4 5 6 7 
Very 
true 
3. I take my high blood pressure medications because I want to take responsibility 
for my own health. 
Not true 
at all 1 2 3 4 5 6 7 
Very 
true 
4. I take my high blood pressure medications because it is a choice I really want to  
make. 
Not true 
at all 1 2 3 4 5 6 7 
Very 
true 
5. I take my high blood pressure medications because it is very important for many 
aspects of my life. 
Not true 
at all 1 2 3 4 5 6 7 
Very 
true 
6. I take my high blood pressure medications because it is consistent with my life  
goals. 
Not true 
at all 1 2 3 4 5 6 7 
Very 
true 
7. I take my high blood pressure medications because I would feel guilty or ashamed 
of myself if I didn’t. 
Not true 
at all 1 2 3 4 5 6 7 
Very 
true 
8. I take my high blood pressure medications because I would feel bad about myself 
if I didn’t. 
Not true 
at all 1 2 3 4 5 6 7 
Very 
true 
9. I take my high blood pressure medications because I feel pressure from others 
(family, friends, care providers, etc) to take them. 
Not true 
at all 1 2 3 4 5 6 7 
Very 
true 
10. I take my high blood pressure medications because others (family, friends, care 
providers, etc) would be upset with me if I didn’t. 
Not true 
at all 1 2 3 4 5 6 7 
Very 
true 
11. I take my high blood pressure medications because I want others (family, 
friends, care providers, etc) to see I can do it. 
Not true 
at all 1 2 3 4 5 6 7 
Very 
true 
12. I take my high blood pressure medications because I want others (family, 
friends, care providers, etc) to approve of me. 
Not true 




For each item, please circle the answer that best expresses your beliefs: 
 
1. Do you sometimes forget to take your high blood pressure pills? 
 Yes      No  
2. Over the past two weeks, were there any days when you did not take your high 
blood pressure medicine? 
 Yes      No  
3. Have you ever cut back or stopped taking your high blood pressure medicine 
without telling your doctor because you felt worse when you took it? 
 Yes      No  
4. When you travel or leave home, do you sometimes forget to bring along your high 
blood pressure medicine? 
 Yes      No  
5. Did you take your high blood pressure medicine yesterday? 
 Yes      No  
6. When you feel like your blood pressure is under control, do you sometimes stop 
taking your medicine? 
 Yes      No  
7. Do you ever feel hassled about sticking to your blood pressure treatment plan? 
 Yes      No  
8. How often do you have difficulty remembering to take all your blood pressure 
medication? 
Never  Almost never  Sometimes  
Quite 
often  Always 
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Following completion of the questionnaires, the co-investigator delivered a short, scripted 
talk on the importance of hypertension management derived from the American Heart 
Association publication What is High Blood Pressure?  
“High blood pressure means the pressure in your arteries is elevated. 
Blood pressure is the force of blood pushing against blood vessel walls. 
No one knows exactly what causes most cases of high blood pressure. It 
usually can’t be cured, but it can be controlled. High blood pressure 
usually has no symptoms. So many people have it and don’t know it.   
 
Not treating high blood pressure is dangerous. High blood pressure 
increases the risk of heart attack and stroke and can damage your kidneys. 
You can live a healthier life if you treat and control it.  Things that you 
can do to help control your blood pressure include taking your medicine 
the way your doctor tells you. 
 
Some medicines, help relax and open up your blood vessels so blood can 
flow through better.  Other medicines keep your body from holding too 





Subjects randomized to the Intervention Group then participated in a session intended to 
provide tactile feedback demonstrating the difference between the subject’s blood 
pressure as measured at check-in and the target pressure recommended by their doctor.  
Tactile feedback was provided by two rubber balls constructed out of commonly 
available sphygmomanometers in which the cuff’s nylon covering was removed and the 
rubber bladder stuffed inside the distal portion of a cotton sock and secured with zip-ties, 
resulting in an inflatable ball of roughly spherical shape (Image 2).  Upon inflation to the 
desired pressure, the rubber hoses leading to the bulb and gauge were clamped using 
hemostats to prevent air leakage. 
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One rubber ball was inflated to 20mmHg (the Reference Ball).  A second ball was 
inflated to 20mmHg plus the difference between the patient’s current SBP and their ideal 
SBP (the Hypertensive Ball).  For example, if the patient’s SBP measured at check-in 
was 160mmHg and their ideal SBP is 120mmHg, the Hypertensive Ball was inflated to 
20 + (160 - 120) = 60mmHg.  The subject was then informed that the difference between 
the two balls was equal to the difference between their actual blood pressure and “where 
your doctor thinks it should be”. 
 
The subject was then asked to take one ball in each hand and squeeze them both 
repeatedly and simultaneously until one arm felt fatigued or for one minute, whichever 
occurred first.  The co-investigator monitored the time using a wristwatch.  In informal 
testing, noticeable unilateral fatigue was reached at approximately 30 squeezes over 20 




Intervention script - extra workload on the heart  
The co-investigator then discussed with the Intervention subject the analogy of this 
fatigue with the added work that is being demanded of their heart due to the same extra 
pressure against which it is constantly and unceasingly working.  The script emphasized 
that the difference in work/fatigue that their arms are experiencing is the same as the 
difference between the resistance that healthy blood pressure would present to their heart 
and its current burden.  Furthermore, while their arm can send conscious signals of 
fatigue, stop working and recuperate, the heart’s signals of pain and fatigue do not rise to 
the level of consciousness and it does not get to rest. 
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“The difference between the bladder pressures is equal to the difference 
between your blood pressure right now and where your doctor thinks it 
should be.  In about half a minute, you were able to feel the difference in 
work that your arm had to exert working against the higher pressure.  You 
heart has to do the same thing, day in and day out without a break.  Your 
arm can send signals to your brain saying that it’s tired and so it gets to 
rest.  But while your heart is working harder, you don’t experience the 
fatigue at a conscious level.  The medications that your doctor has 
prescribed for you will help lower the amount of work that your heart has 
to do.” 
 
The use of scripts for conveying information to subjects was intended to ensure 
consistency of delivery between sessions. 
 
Image 2.  The intervention device consisted of two modified sphygmomanometers with the inflatable bladders repurposed to 






Assessment of immediate motivational impact 
All Intervention and Control subjects were then asked the following question:  “On a 
scale of 1 to 7 with 1 being much less motivated and 7 being much more motivated, how 
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has this session changed your motivation to take your blood pressure medication?”  A 
score of 4 represented “no change in motivation”.  This question was conceived by the 
investigators as a way of evaluating patients’ “gut” reaction to the session outside of any 
more durable changes in motivation or behavior.  It was also considered a way of 
collecting viable motivation data in case of outsized losses to followup.   
  
Demographic, TSRQ, MMAS data and immediate motivational scores were recorded by 
the co-investigator on a deidentified Excel spreadsheet stored on a secure VACT server.  
All original paper documents including consents and questionnaires were stored in a 
locked cabinet in the principal investigator’s locked office. 
 
Followup and chart abstraction 
Subjects were contacted 90 days following the index session for readministration of the 
TSRQ and MMAS via telephone.  If the subject was not available, a message was left 
requesting a callback.  If the subject did not call back within 72 hours, another attempt 
was made.  A maximum of three such attempts were made per subject after which the 
subject was deemed lost to followup.  During these calls both the TSRQ and MMAS 
questionnaires were administered by the co-investigator for comparison to those of the 
index session. 
 
Followup blood pressure data from all patients were abstracted from CPRS from 
regularly scheduled Clinic appointments within +/- 15 days of 90, 180, 270 and 360 days 
following the index session.  Patients with recent hypertension diagnoses typically 
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receive check ups every four to six weeks to determine drug tolerance, efficacy, 
adherence and to address any of the patient’s questions or concerns.  Adjustments to 
treatment regimen are frequently made at this time.  For patients with long-established 
hypertension, appointments every three to six months are typical of the course of care.  
“BP check” appointments are also common and while not a full visit, constituted 
opportunities to gather outcome data.  If no such visit was recorded within the 
appropriate date range, the subject was considered lost to followup for that period.  
Patients could be lost to followup for one period but have a qualifying visit for a later 
period.  For example, several subjects had no qualifying visit 270 days after the index 
session, but did have a “yearly” visit at 360 days. 
 
In keeping with prior studies, subjects’ pharmacy data were extracted to determine the 
Medication Possession Ratio (MPR) for the 360-day periods preceding and following the 
index session (87, 92-94).  The VA maintains electronic records of prescriptions written 
by clinicians (“scripts”) and patient pharmacy activity (“fills”).  The co-investigator 
abstracted script data from CPRS including data on all hypertension medications for each 
subject with active date ranges in 2009, 2010 or 2011.  The abstracted fields included 
medication name, pill count, dosage instructions, start date and end date of the script.  Fill 
data consisted of blocks of dates defined by the date on which the patient filled a 
prescription for a hypertension medication (either in person or via mail) plus the number 
of days supplied as implied by the pill count and dosage instructions (e.g.: “½ tablet three 
times per day”).  The resulting sets of date ranges allowed for comparison between the 
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number of antihypertensive scripts written and filled for any date between 1/1/2009 and 
12/31/2011 for each subject. 
 
If a subject had a script that covered a given day and had not filled that script, the 
resulting score would be 0 for the medication for that day.  Conversely, if the fill data 
indicated that a subject was in possession of the medication on that day, the score would 
be 1.  A given day’s Medication Possession Ratio (MPR) was the sum of such values 
divided by the total number of scripts covering that day.  For example, if a patient had 4 
antihypertensive scripts whose valid dates covered a given day and on that day the 
patient’s fill data indicated possession of only 3 medications, the MPR for that day would 
be 0.75.  Outcome MPR measures were then computed using the average of such ratios 
over the 360 days preceding and following the index visit.   
 
Days which were not covered by a script were not included in the denominator of the 
MPR.  It was believed that this approach provides a more accurate assessment of 
adherence compared to methods used elsewhere which appear to assume that 100% of 
days were covered by a prescription and so calculate MPR using a fixed 360 or 365 days 
in the denominator (95).  In the case where a physician neglects to write a script, such an 
assumption would result in an artificially depressed value for adherence.  A minority of 
patients filled their prescriptions outside the VA system, had no CPRS data for these fills 
and were excluded from this part of the analysis. 
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A cutoff of 80% by pharmacy data is widely used in the literature to define adequate 
medication adherence for a number of diseases.  In the study of antihypertensive regimes, 
this threshold has been associated with a level of drug consumption below which 
adequate control of blood pressure was less likely to be achieved across a number of drug 
classes (17, 96-100).  While this threshold has been criticized by authors as arbitrary and 
overbroad in its application - substantial numbers of non-compliant patients by this 
metric have controlled blood pressures (21) - its use is nevertheless widespread in 
adherence literature and will be employed for this analysis. 
 
All followup, script and fill data were recorded by the co-investigator on a deidentified 
Excel spreadsheet stored on a secure VACT server. 
 
Feasibility 
A second protocol was written and approved for July 15, 2011 to August 15, 2011 during 
which a VACT Clinic doctor and a nurse specializing in care of hypertensive patients 
used the intervention to educate their patients on their disease process.  The intervention 
employed during these sessions differed from the RCT in several important ways: the 
clinicians were free to use the script as they saw fit, explaining the intervention in their 
own words if they found that less disruptive to the rhythm of the clinic visit; the device 
employed during these sessions was substantially modified from that originally used in 
order to facilitate a faster intervention; and, because no followup comparisons were 
contemplated for these subjects, no baseline questionnaires were employed. 
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Structured interviews of both practitioners were performed via email in order to assess 
the practicality and utility of the device in everyday clinical use.  The results of these 
interviews were used to inform questions regarding the feasibility of a larger study and 
overall clinical utility. 
 
The questions used for the interviews were as follows: 
 
How easy was it to find patients for the intervention? 
Was it easy to get people to agree to participate? 
Did patients seem interested in the intervention? 
How easy was it to operate the device? 
How long did a typical intervention take you? 
How much of this time was paperwork vs the actual demonstration? 
Do you think this intervention could be incorporated into your clinical practice? 
Would you use this intervention if the device was available to you? 
Do you think incorporating this intervention would be useful to your patients? 
Do you think this intervention will encourage your patients to change their adherence 
behavior? 




The primary outcome of interest is subject adherence to regime of prescribed medication 
as determined by MMAS at index session and at 90-day followup.  Patient self-reporting 
is direct, simple and inexpensive (101).  Although self-report alone may lead to 
overestimates of adherence, many studies have compared self-report and other 
assessment methods with favorable results and correlate improved levels of self-reported 
adherence with better blood pressure control (102-107).  While a metaanalysis of 86 
studies comparing self-report with nonself-report measures found that only 17% of self-
report measures were highly concordant with electronic measures, questionnaires 
presented the highest concordance (58%) of the self-report methodologies (108). 
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Adherence to an antihypertension regime includes an array of actions beyond timely 
consumption of one or more medicines.  A number of different behaviors are also 
prescribed: losing and maintaining weight, reducing sodium intake, quitting smoking, 
reducing consumption of alcohol, initiating exercise and returning regularly for checkups 
to name a few.  The sheer diversity of these behaviors suggests that a patient’s adherence 
may vary across categories of prescribed activity.  The variable and interacting 
contribution of each behavior to the ultimate goal of lowered blood pressure means that 
simply counting the number of pills the patient takes home from the pharmacy or miles 
logged on a treadmill is unlikely to result in an accurate assessment of adherence.  
Change in blood pressure would seem to be a sufficient measure of adherence, however 
there is often not a straightforward link between this outcome and medical adherence 
(43).  The patient may be obtaining lower blood pressure because of weight loss, exercise 
or even reassurance from the physician or family.  Conversely, a failure to achieve a 
lower blood pressure may be due to poor physiological response to a rigorously followed 
drug plan.  Thus, a focus on blood pressure alone may lead to an incorrect evaluation of 
regimen adherence.   
 
Because no single metric has proven optimal in accurately gauging medical adherence 
(30, 109) four additional metrics were employed to validate and assess the clinical 
significance of the results of any changes in the MMAS: a 7-point Likert scale gauging 
the subject’s sense of any change in adherence motivation administered immediately 
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following the session, electronic prescription fill data, changes in motivation as measured 
by the TSRQ and changes in blood pressure. 
 
Finally, the question of feasibility of a larger study was addressed through structured 
interviews with a primary care doctor and nurse who used the device and intervention in 
their own clinical practices. 
 
Pilot study sample size 
The anticipated sample size for a full study of this intervention is 120 patients.  This 
number is rounded upwards to account for anticipated losses to followup from 102 which 
was the sample size indicated by a standard statistical method for such approximation of 
difference of proportions (Figure 1).  The equation was bounded by the following 
targets/assumptions regarding the primary outcome (change in MMAS): a target p-value 
of 0.05, statistical power of 0.80, standard deviation of 1.6 and a clinically important 
difference between Groups (size effect) of 0.8 on the 8-point scale in keeping with prior 
studies using the same questionnaire (110).  This sample size also agrees with a widely 
employed rule-of-thumb which suggests a minimum of 60 participants per Group for 
single intervention group adherence RCTs (111).   
 
In accord with the recommendations of the Medical Research Council, it was decided that 
a pilot study of 30 subjects was required before embarking on the larger inquiry given the 
novelty of this intervention.  In addition, enrolling 120 subjects would require staffing 
and funding beyond what was feasible with available resources.  While there is no 
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standard in the literature to guide sample size determination for interventional pilot 
studies (112), 30 subjects corresponds to a MMAS size effect of 1.5 points (all other 
assumptions unchanged) which was believed to provide a reasonable balance between a 
realistic target and a workable recruitment goal. 
 





Statistical analyses of continuous data included descriptive statistics, Pearson’s and 
pairwise correlations, OLS regression and t-test comparisons.  Categorical adherence 
measures were analyzed for correspondence and intergroup differences using chi-squared 
analysis and Fisher’s exact tests.  All computations were performed using Excel for Mac 
v. 14.2.0 (Microsoft Corporation, Redmond, WA) and Stata v. 10.1 (StataCorp, College 
























Thirty subjects were enrolled from June 15 to August 15, 2010 resulting in Intervention 
and Control Groups of 15 patients each.  All were male veterans with no statistically 
significant differences in demographics or baseline clinical data between Groups (Table 
1). 
 
The mean age of subjects was 69.7 years (95% CI: 65.3, 74.1) with a range of 44 to 88 
years.  The majority, 21 (15.8, 26.2) were Caucasian with the remainder of subjects 
identifying as African American.  There were 14 (8.3, 19.7) married subjects evenly 
distributed between Groups.  The remaining subjects were either divorced (6 subjects), 
separated (1 subject), widowed (4 subjects) or single (5 subjects).  The average duration 
of hypertension diagnosis at index session was 8.1 years (6.2, 9.9).  Subjects in the 
sample had an average of 11.4 (9.1, 13.6) comorbidities (including hypertension) at 
index.  The average subject took 8.0 (6.2, 9.7) different prescribed medications at the 
time of index session, including 2.9 (2.1, 3.7) hypertension medications.  The average 
number of antihypertensive scripts increased by 0.6 (p = 0.025) during the index visit 
without significant differences between Groups (p = 0.866). 
 
Baseline blood pressures 
Index session SBP, DBP and MAP had no statistically significant differences between 
Control and Intervention Groups (Table 1).  The mean SBP for the sample was 
155.7mmHg (150.2, 161.2), mean DBP 81.9mmHg (76.3, 87.6) and mean MAP of 
106.5mmHg (101.8, 111.2).  Only 9 of 30 subjects were hypertensive by both systolic 
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(≥140mmHg) and diastolic (≥90mmHg) measures, the majority being hypertensive by 
systolic blood pressure only. 
 
Index SBP was negatively correlated with index medical adherence as measured by both 
MPR and MMAS.  Those categorized with low, medium and high MMAS had mean SBP 
of 164.5mmHg (152.8, 176.2), 150.0mmHg (143.7, 156.3) and 153.3mmHg (141.4, 
164.6) respectively.  Between Group differences in index SBP were noted by ANOVA 
for these categories with borderline significance (p = 0.058). However, no significant 
difference in baseline blood pressure was found between those categorized as adherent by 
MPR compared to nonadherent, with mean SBP of 157.8mmHg (139.3, 176.3) and 
156.3mmHg (149.3, 163.2) respectively.  Blood pressure had no other significant 
correlations with demographic or other index visit variables (Table 5). 
 
Baseline motivation 
Baseline adherence motivation was statistically indistinguishable between Intervention 
and Control Groups.  Mean index session TSRQ was 52.9 (48.7, 57.1) out of a possible 
84 points with roughly two-thirds of the contribution from autonomous motivation (Table 
1).  Mean baseline TSRQ was slightly lower in the Intervention Group for both controlled 
and autonomous subtypes.  Index adherence motivation was negatively correlated with 




There were no significant differences between Intervention and Control Groups in 
baseline adherence both in groupwide mean measurements and when the data were 
analyzed categorically (Table 1).  Self-reported adherence for the sample as a whole, as 
measured by mean MMAS was 6.0 (5.2, 6.8) out of a possible 8, which is categorized as 
a “medium” level of adherence according to questionnaire validation studies (85).  
However, the baseline mean 360-day MPR was 54.6% (42.6, 66.8), well below the 
commonly employed 80% adequacy threshold. 
 
As reported elsewhere and consistent with a relatively low specificity of 53% (85), mean 
self-reported scores appeared to overstate adherence levels when compared to pharmacy 
fill data (16, 17, 113).  The majority, 66.7% (52.6%, 87.4%) of subjects self-reported 
medium or high levels of adherence by MMAS.  In contrast to MMAS, less than one 
quarter of subjects, 23.1% (5.7%, 40.4%) were classified as adherent by medication 
possession.  Index MPR was lower in the Intervention Group but the difference was not 
statistically significant.  
 
The two metrics for index medical adherence were positively correlated with a significant 
slope coefficient indicating an 8.6% (4.3, 12.9) increase in fill rates for every 1 point 
increase in self-reported adherence (R2 = 0.418) (Figure 2, left).  Chi-squared measure of 
association between the categories of adherent/nonadherent for MPR and 
low/medium/high for MMAS was suggestive of good concordance but of borderline 
significance (χ2 = 4.178, p = 0.124).  Fisher’s Exact test resulted in similar significance (p 
= 0.157).  Of the 6 subjects who were adherent by MPR, none were “low” adherers by 
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MMAS, 3 were classified as “medium” and 3 were “high”; of the 20 subjects classified as 
nonadherent by MPR, 9 were “low” adherers by MMAS, 6 were “medium” and 5 were 
“high” (Figure 2, left). 
 
The inverse relationship between MMAS and baseline blood pressure noted above is 
consistent with the results of prior studies (85).  For the study sample, each 1 point 
increase in MMAS was associated with a 3.1mmHg (-0.7, -5.5) decrease in index SBP 
(R2 = 0.202) (Figure 2, right).  The average SBP for medium and high adherers by 
MMAS was 151.8mmHg and 165.7mmHg for low adherers.  As with MMAS, higher 
levels of MPR appeared to predict lower index blood pressure (-16.7mmHg SBP per 10% 
increase in MPR).  However, the sample size was insufficient to establish the significance 
of this relationship.  
 
In addition to lower index blood pressure values, better results for both adherence metrics 
were associated with lower scores for controlled motivation, higher scores for 
autonomous motivation, longer duration of disease and Caucasian race.  The strength and 
significance of these associations was typically higher for medication possession ratio 
than for self-reported adherence (Table 5). 
 
Immediate motivational impact 
Subjects’ sense of their immediate motivational response to the index session as 
measured by their answers to a 7-point Likert-type question was positive and significant 
in the Intervention Group but not in the Control Group (p <0.001) (Table 1).  
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A response of 4 indicated no change in motivation.  The mean response for the question 
in the sample as a whole was 5.3 (4.8, 5.8) indicating a moderately positive impact on 
motivation from the session.  Higher numbered responses were significantly correlated 
with shorter history of hypertension and larger improvements in self-reported adherence 
at 90 days (Table 5). 
 








Changes in blood pressure 
Both Groups exhibited decreases in mean SBP and MAP relative to index levels for every 
followup period (Table 2).  Blood pressure decreases were apparent at 90 days and 
Mean 95% CI Mean 95% CI p Mean 95% CI Mean 95% CI p
Demographics Motivation (TSRQ)
  n 15 15   n 15 15
  Male 15 15 1.000   Autonomous 38.2 (36.1, 40.3) 37.7 (35.1, 40.3) 0.756
  Caucasian 11 (10.8, 11.2) 10 (9.8, 10.2) 0.703   Controlled 15.8 (10.6, 21) 14.2 (8.6, 19.8) 0.684
  Married 7 (6.7, 7.3) 7 (6.7, 7.3) 1.000   Total 54.0 (47.8, 60.2) 51.9 (46.5, 57.2) 0.613
  Age in years 72.5 (66.0, 79.1) 66.9 (60.5, 73.2) 0.193 Adherence
  Dx in years 8.1 (5.8, 10.3) 8.1 (5.2, 11) 0.968   Self-report (MMAS) 6.3 (5.4, 7.3) 5.7 (4.5, 6.9) 0.451
  Comorbidities 10.7 (7.6, 13.9) 12.0 (9.2, 14.8) 0.563     n (%) 15 (100%) 15 (100%)
  Medications 7.7 (5.7, 9.6) 8.9 (6, 11.7) 0.490       Low (<6) 4 (27%) 6 (40%) *
  HTN medications 2.3 (1.7, 2.9) 3.5 (2.2, 4.7) 0.135       Medium (6 to <8) 6 (40%) 5 (33%) *
Blood pressure       High (8) 5 (33%) 4 (27%) *
  n 15 15   Pharmacy data (MPR) 63.3% (0.47, 0.79) 47.4% (0.31, 0.63) 0.185
  Systolic 153.3 (145.8, 160.8) 158.1 (150.7, 165.6) 0.382     n (%) 12 (100%) 14 (100%)
  Diastolic 81.5 (75.2, 87.8) 82.4 (73.3, 91.5) 0.869       Nonadherent (<80%) 8 (67%) 12 (86%) *
  Mean arterial pressure 105.4 (100.1, 110.7) 107.6 (100.2, 115.1) 0.636       Adherent (>=80%) 4 (33%) 2 (14%) *
Immed. motivation impact
* X^2, p-value for MMAS 0.602, 0.740; for MPR 1.321, 0.250   7-point Likert scale 4.3 (3.9, 4.6) 6.3 (5.7, 6.8) 0.000
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persisted with little additional change through 360-day followup.  The mean decline in 
SBP was 16.9mmHg (6.3, 27.4) at 90 days and 15.7mmHg (7.2, 24.1) at 360 days.  
Significance for 180-day and 270-day data suffered from outsized losses to followup as 
discussed below. 
 
In general, the magnitude, duration and statistical significance of the declines in blood 
pressure were greater for the Intervention Group, however between Group differences 
were not statistically significant.  The strength of the relationship of the intervention with 
these improvements was low by Pearson correlation, with r = 0.057 between the 
intervention binary variable and 90-day change in SBP.  At 90-day followup, the 
Intervention Group exhibited a mean decline in MAP of 10.3mmHg (p = 0.031) whereas 
the Control Group had a mean decline of 7.6mmHg (p = 0.275).  Blood pressure changes 
persisted through the end of the followup period with mean MAP declines of 12.2mmHg 
(p = 0.008) and 6.0mmHg (p = 0.164) for the Intervention and Control Groups 
respectively at 360 days.   
 
Higher index MAP was associated with larger declines following the index session.  A 
1mmHg elevation in baseline MAP was associated with a subsequent decline of 
0.862mmHg (0.436, 1.290) at 90-day followup (R2 = 0.485).  This effect was consistent 
in direction for both Intervention and Control Groups but was greater and more 
significant in the Intervention than the Control which underwent percentage declines in 
MAP of 8.6% (1.5%, 15.8%) and 5.6% (-7.6%, 18.8%) respectively. 
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Changes in motivation 
The mean TSRQ response at 90-day followup was suggestive of increased levels of 
motivation for both Groups, with a mean response of 55.8 (50.4, 61.1) corresponding to 
an increase of 2.7 points (-1.4, 6.8) compared to baseline, however significance of this 
relatively small change was limited by sample size (Table 3) and between Group 
differences were not statistically significant.  Almost all of this effect was due to an 
increase of 4.5 points in controlled motivation in the Intervention Group (r = 0.119).  
Autonomous motivation was little changed for the sample as a whole with an increase of 
0.1 (-2.0, 2.3). 
 
The increase in controlled TSRQ for the Intervention Group was countered by a slight 
decline in autonomous motivation.  The slight increase in motivation for the Control 
Group was evenly distributed between autonomous and controlled motivation.   
 
Mean 95%CI Mean 95%CI p ! v index 95%CI p ! v index 95%CI p
SBP
  Index 153.3 (145.8, 160.8) 158.1 (150.7, 165.6) 0.382 - - - - -
  90 days 139.8 (128.1, 151.5) 139.5 (129.8, 149.1) 0.965 -18.2 (-36.4, 0) 0.081 -15.6 (-25.9, -5.4) 0.014
  180 days 140.4 (128.3, 152.6) 144.5 (128.8, 160.2) 0.691 -14.3 (-28.4, -0.2) 0.095 -11.2 (-25.4, 3) 0.184
  270 days 137.2 (129.7, 144.6) 148.8 (134.8, 162.7) 0.141 -16.4 (-24.5, -8.2) 0.003 -7.9 (-21.2, 5.5) 0.286
  360 days 141.2 (132.1, 150.3) 141.5 (134.4, 148.6) 0.953 -14.3 (-29, 0.4) 0.090 -16.9 (-24.6, -9.2) 0.002
DBP
  Index 81.5 (75.2, 87.8) 82.4 (73.3, 91.5) 0.869 - - - - -
  90 days 81.1 (72.7, 89.5) 74.0 (67.7, 80.3) 0.195 -2.3 (-13.2, 8.6) 0.687 -7.6 (-17.4, 2.1) 0.155
  180 days 79.1 (71.2, 87.1) 75.7 (65.2, 86.1) 0.608 1.1 (-10, 12.3) 0.848 -6.3 (-14, 1.3) 0.164
  270 days 80.4 (74.5, 86.2) 78.4 (71.4, 85.4) 0.674 -3.8 (-10.3, 2.7) 0.279 -10.5 (-19, -2) 0.047
  360 days 76.1 (71.9, 80.3) 71.5 (64.3, 78.6) 0.296 -1.8 (-8.1, 4.5) 0.588 -9.9 (-17.7, -2.1) 0.032
MAP
  Index 105.4 (100.1, 110.7) 107.6 (100.2, 115.1) 0.636 - - - - -
  90 days 100.7 (92.1, 109.2) 95.8 (89.3, 102.3) 0.380 -7.6 (-20.4, 5.2) 0.275 -10.3 (-18.4, -2.3) 0.031
  180 days 99.6 (91.7, 107.4) 98.6 (88.3, 108.9) 0.884 -4.0 (-14.3, 6.3) 0.476 -7.9 (-15.7, -0.2) 0.099
  270 days 99.3 (93.7, 104.9) 101.8 (94.4, 109.2) 0.594 -8.0 (-13.9, -2.1) 0.024 -9.6 (-18.6, -0.6) 0.075
  360 days 97.8 (93.6, 102) 94.8 (89.4, 100.2) 0.409 -6.0 (-13.7, 1.8) 0.164 -12.2 (-19.5, -5) 0.008
Control Intervention Control Intervention
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Changes in adherence 
Mean adherence improved for the Intervention Group and was close to unchanged for the 
Control Group as measured by MMAS and MPR with statistical significance varying by 
measure (Table 4).  Pearson correlation coefficients between the intervention and 
outcome measures were 0.210 and 0.271 for point change in MMAS and percent change 
in MPR respectively.  Between Group differences were not statistically significant 
(MMAS p = 0.349, MPR p = 0.181). 
 
The combined sample underwent almost no change in self-reported adherence at 90 days 
with a change of -0.2 (-0.8, 0.4) points on the 8-point MMAS.  The Intervention Group 
had a mean improvement of 0.5 (-0.5, 1.5) points, however the result was not significant. 
 
The sample as a whole exhibited an increase in mean 360-day medication possession 
ratio of 6.3% (0.0%, 14.5%) improving from 54.7% (42.6%, 66.8%) to 60.9% (53.8%, 
68.0%) but remaining below the 80% threshold for adequate adherence.  The majority of 
this change was due to improvement in the Intervention Group where the average MPR 
Mean 95%CI Mean 95%CI p ! v index 95%CI p ! v index 95%CI p
Autonomous
  Index 38.2 (36.1, 40.3) 37.7 (35.1, 40.3) 0.756 - - - - - -
  90 days 39.0 (36.8, 41.2) 36.5 (32.4, 40.6) 0.293 1.2 (-1, 3.3) 0.311 -1.0 (-4.5, 2.5) 0.590
Controlled
  Index 15.8 (10.6, 21) 14.2 (8.6, 19.8) 0.684 - - - - - -
  90 days 16.5 (11.9, 21.1) 19.5 (12.4, 26.6) 0.493 0.8 (-2, 3.7) 0.569 4.5 (-1.6, 10.6) 0.174
Total TSRQ
  Index 54.0 (47.8, 60.2) 51.9 (46.5, 57.2) 0.613 - - - - - -
  90 days 55.5 (49.5, 61.6) 56.0 (47.4, 64.6) 0.931 2.0 (-2.3, 6.3) 0.318 3.5 (-3.3, 10.3) 0.335
ControlControl Intervention Intervention
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increased 11.3% (0.0%, 23.3%, p = 0.088) while the Control Group improved by 0.7%  
(-8.8%, 9.6%). 
 
Two of the subjects in the Intervention Group had baseline 360-day MPR of zero and 
started filling their scripts (with variable consistency) following the index session.  This 
resulted in a low baseline MPR for the Intervention Group and contributed to its 
relatively large increase in mean adherence.  Removing these patients from the 
calculation results in a mean increase in MPR of 5.0% (p = 0.255) for the Intervention 
Group.  There were no similar patients in the Control Group.   
 
Improvement in MMAS was positively correlated with index SBP, controlled and 
aggregate motivation (TSRQ) at index visit and scores indicating higher immediate 
motivational impact from the session.  Improvement in MPR was likewise positively 
correlated with baseline motivation (controlled and total TSRQ) (Table 5).  Lower levels 
of improvement and even negative changes in adherence were associated with longer 
disease burdens and higher baseline adherence.  These relationships were consistent 
across both MMAS and MPR.  The association between length of diagnosis and 
adherence intervention efficacy has been noted in prior studies (22, 66).   
 
Table 4.  Changes in adherence as measured by MMAS and MPR, index visit vs 90-day followup 
 
 
Mean 95%CI Mean 95%CI p ! v index 95%CI p ! v index 95%CI p
MMAS
  Index 6.3 (5.4, 7.3) 5.7 (4.5, 6.9) 0.451 - - - - - -
  90 days 6.1 (5.4, 6.8) 6.6 (5.9, 7.3) 0.330 -0.1 (-0.7, 0.5) 0.798 0.5 (-0.5, 1.5) 0.372
MPR
  Pre-index 63.3% (0.47, 0.79) 47.4% (0.31, 0.63) 0.185 - - - - - -
  Post-index 64.1% (0.55, 0.74) 58.7% (0.49, 0.68) 0.487 0.7% (-0.1, 0.1) 0.934 11.3% (0, 0.2) 0.088
Control Intervention Control Intervention
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Table 5.  Pairwise correlation coefficients 
 
 
Pearson correlation coefficients between the intervention Boolean variable and outcome 
measures were 0.76, 0.21, 0.27, 0.12 and 0.06 for immediate change in motivation, point 
change in MMAS, percent change in MPR, point change in TSRQ and mmHg change in 
SBP respectively.   
 
Losses to followup 
Losses to followup varied by dataset.  Blood pressure followup window periods 
sometimes did not coincide with clinic visits and thus no blood pressure data were 
available in CPRS for some patients for some periods (Table 6).  Losses to followup for 
both Control and Intervention Groups for the 90-day and 360-day samples were 33% and 
27% respectively. The 180-day and 270-day blood pressure datasets had even larger 
losses.  Baseline blood pressure characteristics for those lost to followup at 90 days were 
asymmetric between Groups.  The Control Group lost 5 subjects with average index 
blood pressures below the Group’s mean.  Conversely, the Intervention Group lost 4 
subjects with relatively high index blood pressures.   
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
1 Age - Index demographics and clinical data
2 Caucasian 0.33
3 Married 0.13 0.18
4 HTN years 0.26 0.11 0.12
5 Comorbidities -0.01 -0.25 0.08 0.46
6 Medications -0.38 -0.21 -0.15 0.27 0.59
7 HTN medications -0.26 -0.20 -0.19 0.42 0.45 0.62
8 Index SBP 0.08 -0.07 -0.09 -0.04 0.08 -0.11 0.08
9 TSRQ Autonomous -0.23 -0.32 -0.16 0.12 0.00 -0.04 -0.16 0.12 Index motivation metrics
10 TSRQ Controlled 0.08 -0.11 0.19 -0.12 -0.32 -0.36 -0.24 -0.06 -0.45
11 TSRQ Total -0.02 -0.23 0.11 -0.06 -0.30 -0.36 -0.30 -0.01 0.36 0.91
12 MMAS 0.25 0.29 0.16 0.37 0.02 0.10 0.10 -0.45 0.07 -0.65 -0.57 Index adherence metrics
13 MPR 0.04 0.24 0.30 0.50 -0.07 0.24 -0.01 -0.33 0.44 -0.57 -0.42 0.65
14  ! immed. motivation -0.04 0.08 0.01 -0.67 -0.02 0.00 0.12 0.40 -0.07 0.01 -0.02 -0.15 -0.34 Followup data
15 90d ! SBP -0.26 -0.06 -0.07 -0.15 0.31 0.34 0.03 -0.68 -0.06 -0.24 -0.25 0.30 0.18 -0.09
16 90d ! TSRQ Auton. -0.16 0.02 0.17 -0.18 0.02 0.38 0.18 -0.17 -0.33 0.19 0.04 -0.01 0.26 -0.01 0.19
17 90d ! TSRQ Control. -0.22 -0.20 -0.09 -0.23 0.21 0.34 0.19 0.12 0.09 -0.44 -0.38 0.07 0.11 0.18 0.45 0.02
18 90d ! TSRQ Total -0.27 -0.16 0.01 -0.29 0.19 0.48 0.25 0.01 -0.10 -0.27 -0.30 0.05 0.23 0.14 0.46 0.54 0.85
19 90d ! MMAS -0.23 -0.27 0.14 -0.45 -0.14 -0.06 -0.19 0.57 -0.01 0.61 0.55 -0.82 -0.36 0.36 -0.29 0.21 -0.06 0.05
20 ! MPR -0.16 -0.20 -0.27 -0.46 0.03 -0.19 0.08 0.15 -0.14 0.53 0.47 -0.57 -0.82 0.16 -0.07 -0.29 0.00 -0.14 0.28
Bolded correlations are significant at the 10% level.
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Loss to followup for the questionnaire data was of lower magnitude than that for blood 
pressure measurements.  Subjects were considered lost if the co-investigator was 
unsuccessful in contacting them despite three attempts via phone.  However, OLS 
regression indicates a very weak positive relationship between index TSRQ and change 
in TSRQ with a slope not significantly different from zero.  Thus, while the Control 
Group lost subjects with relatively high index motivation and the Intervention Group lost 
relatively low motivation subjects, this asymmetry seems unlikely to have caused 
significant bias in their subsequent changes in TSRQ.  Both Groups lost patients with 
lower index adherence as measured by MMAS. 
 
One subject died of an unrelated illness during the year following the index visit.  The 
subject had already undergone his followup questionnaires but analysis of his script fill 
behavior was limited to 180 days before and following the index visit. 
 





An additional seven subjects were enrolled from June 15 to August 15, 2011 (the year 
following the RCT) as part of the feasibility component of this pilot study.  These 
Mean at Loss to Mean at Loss to Mean at Loss to Mean at Loss to
n index followup n index followup n index followup n index followup
SBP TSRQ
  Index 15 153.3 0% 15 158.1 0%   Index 15 54.0 0% 15 51.9 0%
  90 days 10 158.0 33% 11 155.1 27%   90 days 13 53.5 13% 12 52.5 20%
  180 days 7 154.7 53% 6 155.7 60% MMAS
  270 days 11 153.5 27% 8 156.6 47%   Index 15 6.3 0% 15 5.7 0%
  360 days 10 155.5 33% 11 158.5 27%   90 days 13 5.4 13% 12 4.9 20%
Control Intervention Control Intervention
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subjects were introduced to the intervention by a doctor (n = 4) in the course of a regular 
Clinic appointment or a nurse (n = 3) specializing in the instruction of patients in the use 
of home blood pressure monitoring systems.  An identical script was used for the 
intervention but was not required to be read by the clinician.  The aim was to assess the 
viability of the use of the device and intervention in everyday clinical practice.  No data 
on these patients were collected beyond demographics and no subjects served as controls. 
 
The physician reported positive reception from his patients and favorable opinion of the 
intervention, describing it as “incredibly easy” to use and “a very impressive tool” for 
patient education.  His assessment of patient experience was that they were typically 
“very eager” to participate when asked.  Patients were interested in the intervention and 
smiled, showing positive body language while using the device.  He estimated that a 
typical intervention took 5 minutes of which the majority was usually occupied by the 
consent process.  He believed that the intervention was suitable for most people 
regardless of educational level, and that “a large segment of [his] patients” would find the 
intervention useful.  However, he was unsure whether the intervention would actually 
change adherence behavior and noted that “it certainly can’t hurt”.  He felt that the 
intervention was a novel tool for use in addition to the traditional printed, web-based and 
verbal vectors.  
 
The physician believed that he would likely make use of the device and intervention in 
clinical practice but that it might be best employed by a healthcare extender such as a 
nurse or health technician.  He noted that it was sometimes hard to find time to employ 
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the intervention given all that is required of a primary care visit and that use of the device 
requires no specialized knowledge or skillset which would preclude use by a non-
physician. 
 
The nurse also reported very positive reception from her patients.  It was easy to find 
suitable patients and they were generally eager to participate and interested in the device 
once it was explained to them.  She felt that the device was easy to operate but that the 
pressure seemed to leak out over time.  She estimated that a typical intervention took 15 
minutes including explanation of the balls’ use and the meaning of the pressure 
differences.  She estimated that only 5 minutes of this time was used for the actual 
intervention, the remainder dedicated to the consent process. 
 
She felt that the device could easily be incorporated into her clinical practice and would 
“definitely” use the device were it available.   She noted that “this intervention may 
motivate them and encourage them to be more serious about taking their medication... I 
definitely feel that this intervention would help.  I always think that visual aids and 
hands-on always helps a patient learn... will definitely improve patient adherence 
behavior”.  She concluded, “this is a fairly simple intervention and would be well suited 
for several types of patients.  I also do group visits with diabetes and hypertension 
[where] I would like to use this intervention, if available, as a teaching tool.” 
 
There was no formal assessment of patient satisfaction or opinion of the intervention.  




Poor adherence to prescribed antihypertensive medication has been characterized by the 
National Council on Patient Information and Education as “America’s other drug 
problem” (114).  More than sixty-five million Americans and one billion people 
worldwide have blood pressure high enough to warrant treatment.  Studies in the United 
States consistently report adherence to antihypertensive regimes of 30%-60%, well below 
the 80% threshold commonly associated with consistent blood pressure control.  The 
sequelae of untreated hypertension are serious and their burden to the patient and 
economic cost to society are substantial.  Prior inquiries have established that patients are 
less apt to adhere to prescribed treatments for asymptomatic diseases (14).  Thus, it seems 
worthwhile to investigate the effect of providing a conscious, subjective awareness (i.e., a 
symptom) to the usually asymptomatic pathology of hypertension.  The aim of this pilot 
randomized controlled study was to determine the utility of a somatosensory educational 
intervention to improve adherence to prescribed antihypertensive regimes and the 
feasibility of a full-scale trial.  The results of the inquiry suggest that the intervention 
shows promise in promoting adherent behavior and may encourage clinically useful 
improvements in blood pressure.  The results of recruitment efforts and the comments 
from practitioners suggest that a larger scale study is feasible in the clinical setting.  The 
intervention presents feedback directly calibrated to the individual patient’s level of 
disease in the moment, it is inexpensive, simple, noninvasive, easily understood and 
appears feasibly integrated into the rhythm of the typical clinic visit.  A larger study is 
required to confirm these results and establish their statistical significance. 
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Several metrics of adherence were investigated as well as motivation and blood pressure 
before and after the intervention in order to gain a preliminary assessment of clinical 
utility.  Generally speaking, the mean changes in measures of interest were encouraging 
for the intervention but significance and generalizability were seriously limited by sample 
size and homogeneity.  Cohen’s Rule of Thumb classifies the effect size of the 
Intervention on immediate motivational impact as “high” with a correlation of 0.76.  
Higher levels of immediate motivational impact, in turn, were significantly associated 
with greater subsequent improvement in self-reported adherence.  Effect sizes on the 
outcome measures of point change in MMAS, percent change in MPR, point change in 
TSRQ and mmHg change in SBP were classified as “small” (0.10 to 0.25) to “medium” 
(0.25 to 0.50) (115).  However, modest effect size does not preclude clinical relevance 
particularly in the case of low cost, high prevalence interventions (116). 
 
These size effects are consistent with those found by Roter and colleagues whose meta-
analysis of efforts to improve antihypertensive adherence noted larger intervention effect 
sizes on indirect measures such as MPR and small effects on subjective measures such as 
MMAS and health outcomes such as SBP (71).  This discrepancy may be explained by a 
possible ceiling effect in index visit MMAS reducing room for post-intervention 
improvement as compared to changes in MPR and blood pressure which are not limited 
by the same ex ante inflation.   
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Scientists have identified many factors associated with poor adherence in the treatment of 
hypertension.  Demographic, economic, disease- and treatment-specific variables all play 
a role.  The disease is largely insensible and many of the medications are associated with 
serious side effects including sexual dysfunction, cough, dizziness, nausea, headache and 
other effects of autonomic dysregulation.  Furthermore, unlike treatments for other 
illnesses, antihypertensives do not generally provide negative reinforcement in the form 
of relief from consciously experienced symptoms.  For a patient considering taking 
his/her antihypertensives, the drawbacks of adherence are quite clear: side effects, 
inconvenience and money.  The benefits are usually nebulous - “long life”, 
“cardiovascular health”, “improved quality of life” - and the risks of nonadherence are 
equally abstract, distant and uncertain.  The pathology itself is detected by an occult and 
unexplained process, measured and discussed using a ratio of two undefined numbers 
presented in the unhelpful units of “millimeters of Mercury”.  In one survey of 587 
patients under treatment for hypertension, fully 80% reported reservations about taking 
their antihypertensive medicine and 66% preferred to lower their blood pressure without 
medication (117). 
 
There is a substantial body of inquiry seeking to identify successful interventions to 
improve antihypertensive adherence and clinical outcomes.  Categories of intervention 
include education, dose simplification, motivational approaches and combinations of 
these efforts.  Modalities include lecture, interactive sessions, improved access, self-
monitoring, reminders and rewards among many others.  Although not amounting to a 
consensus among researchers, several reviews cite advantages to multi-approach, patient-
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specific interventions (51, 69, 71, 72, 74).  Unfortunately, such approaches are typically 
complex, expensive and difficult to implement.  Thus, there is interest in simple, patient-
specific interventions capable of producing clinically relevant improvements with the 
possibility of realistic administration during the office visit (45).  This individually 
tailored intervention addresses the problems of expense and complexity in that it is 
unimodal, easily administered by one caretaker, requires no followup reinforcement and 
employs a device fabricated from widely available, inexpensive components. 
 
Data on the benefits of educational sessions are mixed at least in part due to widely 
varying modalities, venues, frequencies of teaching sessions and outcome measures.  In 
the largest, best-designed and most often-cited interventions, education-only efforts fare 
poorly.  Of the six educational RCTs sufficiently rigorous to be included in the latest 
Cochrane Review of interventions to improve antihypertensive adherence (51), only one 
relatively small trial (n = 110) of group education sessions by Marquez-Contreras et al 
demonstrated improved adherence but evinced no effect on clinical outcomes (118).  
Pierce and colleagues, in a study of 115 patients, found that a set of four office-based 
educational sessions had a larger impact on blood pressure control and adherence by pill-
count than daily pressure monitoring (54).  In contrast, an earlier landmark study by 
Sackett et al found that mastery by 230 steelworkers of facts regarding hypertension and 
its sequelae provided and reinforced at work elicited no improvement in adherence (57).  
Kirscht et al, in a study of 400 almost entirely Caucasian patients identified no 
improvement in adherence from an educational session employing written material as 
part of four sequential multi-approach interventions.  Similarly, Webb and colleagues 
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noted no improvement in either adherence or blood pressure in 123 low-income African-
American patients who received additional education and psychosocial counseling when 
compared to those receiving regular family physician care (55).  Finally, Kerr and 
colleagues identified significant improvements in pill-count adherence from 
combinations of self-monitoring and education, but no such improvements when 
education was utilized alone (52).  Were the results of the present inquiry supported in a 
larger study, this intervention may add a standalone educational initiative capable of 
encouraging improvements in medication possession and blood pressure management to 
the armamentarium of clinicians and researchers. 
 
Self-reported medical adherence, the primary outcome as measured by mean MMAS, 
was improved in the Intervention Group and slightly decreased in the Control.  Greater 
levels of improvement in MMAS were associated with responses indicating greater 
immediate motivational impact from the intervention.  Encouragingly, this latter metric 
evidenced a “high” size effect from the intervention according to Cohen’s Rule of 
Thumb.  As with prior studies, self-report in the sample appeared to overstate adherence 
levels both at baseline and followup when compared to more objective measures. 
 
Intervention Group MMAS responses demonstrated a mean increase of 0.5 points out of 
8 (p = 0.372) moving from a “low” level of adherence (<6 points) to “medium” (6 to <8 
points).  The study was powered to detect a difference of 1.5 points and thus could not 
establish the significance of this result.  However, were this difference to persist upon 
further investigation, such an improvement would likely accompany clinically relevant 
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blood pressure improvements on average.  Crossing this threshold has been shown to 
have clinical significance.  In a study of 1367 patients, Morisky et al found that 67.2% of 
“low” adherers by MMAS had uncontrolled hypertension compared to 55.2% of 
“medium” adherers (85).  Krousel-Wood et al, in a study of 116 patients, found that the 
odds-ratio for non-persistence (<80% adherence by MPR) decreased from 8.2 to 2.3 for 
the same change in MMAS category (87). 
 
In order to validate and explore the clinical significance of the primary outcome, three 
secondary outcomes were examined.  The results of these analyses also suggest a positive 
impact from the intervention on medication possession ratios, motivation for adherence 
and clinically relevant improvements in blood pressure. 
 
Medical adherence as measured by 360-day MPR increased 11.3% (p = 0.088) in the 
Intervention Group and 0.7% (p = 0.934) in the Control.  However, the study was not 
sufficiently powered to detect a between-Group difference.  Of all the outcome variables, 
the estimate of size effect by Pearson correlation was highest between the intervention 
and MPR.  Unfortunately, the average post-intervention MPR of 58.7% is still well below 
the threshold of 80% commonly used to define adequate adherence for antihypertensives.  
This persistence is perhaps unsurprising given that the study sample included only 
patients with uncontrolled hypertension despite treatment.  This result emphasizes the 
multifactorial approach of successful interventions; on average, use of this device alone is 




Self-Determination Theory proposes that autonomous motivation is an essential 
component of durable changes in health behaviors (46).  Subjects’ response to the 
question of immediate change in motivation substantially and significantly favored the 
Intervention (p < 0.001) and more positive responses to this question were significantly 
associated with greater improvements in MMAS.  This question was intended to gauge 
patients’ “gut” response to the intervention outside of any changes that it may or may not 
precipitate in their motivation or behavior.  It was also conceived as a safeguard against 
poor questionnaire followup.  Because the question was not vetted for content validity, 
predictive validity or reliability, the importance of this result is unclear.  Nevertheless, 
this result and the clinicians’ feedback are encouraging for a larger study as they suggest 
that patients find the intervention interesting and useful as a heuristic device.   
 
Although patients’ endorsement of the immediate impact of the intervention on 
motivation was encouraging, the question did not distinguish between forms of 
motivation and the followup data are much more ambiguous.  None of the changes in 
motivation were significant at 90 days and mean changes indicated an increase in the 
controlled motivation subcategory.  In fact, there is no reason to believe that one session 
of the intervention should have a durable impact on feelings of competence or encourage 
autonomous forms of motivation.  On the contrary, it is possible that the intervention was 
viewed by subjects as an attempt to elicit feelings of guilt or shame which are examples 
of controlled influences and are usually counterproductive. 
 
 49 
Higher levels of controlled motivation are often (but not always (95)) associated with 
poorer adherence and health outcomes.  However, SDT also proposes that behavioral 
change involves the internalization of initially external influences (47) and that 
motivation is a dynamic concept in which a patient experiencing a controlled motivation 
type can eventually internalize this influence (46).  It is plausible that an initially 
controlled influence from the intervention could ultimately become integrated into more 
self-derived sources of motivation and enhance the patient’s sense of self-efficacy in the 
longer run.   
 
Both the Control and Intervention Groups appeared to experience durable, clinically 
useful, statistically significant mean improvements in SBP and MAP.  Mean 
improvements were greater in magnitude, duration and statistical significance in the 
Intervention Group.  In a landmark recommendation, The National High Blood Pressure 
Education Program emphasized that a sustained reduction of even 5mmHg in SBP was 
shown to reduce mortality from cardiovascular disease by 7% per year (119).  Thus, were 
a larger study to affirm these reductions in blood pressure, such changes would have 
clinical relevance.  
 
Any effect from the session on blood pressure was heavily confounded by index visit 
changes in number of antihypertensives.  The average subject increased their number of 
antihypertensive scripts by 0.6 (p = 0.025) during the index visit.  This change was seen 
equally in both Groups.  New antihypertensives given at index visit would provide 
explanation for the symmetry of blood pressure improvements between Groups and the 
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poor estimate of the intervention effect size on change in 90-day SBP despite a 
significant improvement in MPR.  Interestingly, regression of blood pressure changes on 
number of new scripts did not result in significant slope coefficients or measures of 
association.  In addition, new medications were evenly distributed between Groups and 
so would not explain the greater apparent durability of improvements in the Intervention 
Group. 
 
A number of different behaviors are prescribed and proscribed with the ultimate goal of 
blood pressure control.  Thus, it is possible that the index visit (both Control and 
Intervention sessions) encouraged pressure reductions through behavioral changes not 
captured by the adherence and motivation outcome measures utilized for this study.  
Indeed, several trials of educational interventions have noted similar reductions in blood 
pressure in control Groups exposed to regular care, particularly for studies which focus 
on patients with poor medical adherence (49, 59).  Studies of biases have found that rates 
of adherence in clinical trials are typically high due to attention effect (120).  However, 
while both Groups received the informational talk on the benefits of antihypertensive 
adherence, it seems unlikely and is inconsistent with prior studies (14) to believe that 
such a brief and unexceptional lecture precipitated the improvements noted in the present 
study.  It may be more plausible to assert that hypertensive patients under care of primary 
care physicians will, on average, achieve a fall in their blood pressure through various 
avenues including addition of new drugs - an effect which the intervention may have 
augmented.   
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Baseline blood pressure characteristics for those lost to followup at 90 days were 
asymmetric between Groups.  The Control Group lost 5 subjects with average index 
blood pressures below the Group’s mean.  Conversely, the Intervention Group lost 4 
subjects with relatively high index blood pressures.  As discussed above, 90-day change 
in blood pressure was inversely and significantly related to index SBP with a slope of 
roughly -1.  Thus, the magnitude of the Control Group’s reduction in BP at 90 days may 
have been biased upwards (by roughly 5mmHg) and that of the Intervention Group may 
have been biased downwards (by roughly 3mmHg).  The combination of these influences 
could have led to a low estimate for impact on blood pressure from the intervention. 
 
Correlations between demographic data, baseline adherence and changes in adherence 
metrics were largely in line with prior inquiries and common sense.  Baseline blood 
pressures were negatively and significantly correlated with better adherence as measured 
by both self-report and prescription data.  Index motivation was negatively correlated 
with duration of disease, number of comorbidities and number of medications.  The two 
metrics for index medical adherence (MMAS and MPR) were positively correlated.  In 
addition to lower index blood pressure, higher baseline values for both adherence metrics 
were associated with lower scores for controlled motivation, higher scores for 
autonomous motivation, longer length of diagnosis and Caucasian race.   
 
Improvement in MMAS was positively correlated with index SBP, controlled and 
aggregate motivation (TSRQ) at index visit and a higher immediate motivational impact 
from the session.  Improvement in MPR was likewise positively correlated with baseline 
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motivation (controlled and total TSRQ).  Longer disease burdens were associated with 
higher baseline adherence, reduced immediate motivational impact as well as lower 
levels of improvement and even negative changes in adherence by MMAS and MPR.   
 
Feasibility of a larger study 
The feasibility of a larger study was evaluated through implementation of a small number 
of interventions on a randomized convenience sample of patients at a busy primary care 
clinic, followed by structured interviews with clinicians who instituted the intervention in 
their everyday practice.  These results suggest that a larger scale study wherein the 
intervention is administered by working care extenders such as RNs, PAs and/or research 
assistants in the primary care setting is feasible and would not be unacceptably disruptive 
to the everyday flow of clinical practice.   
 
Patients typically expressed curiosity regarding the device and appeared pleasantly 
surprised at the novelty of the concept.  There were no complaints or withdrawals from 
the study and patients typically responded with interest and curiosity when the 
intervention was described and during the demonstration.  The physician who employed 
the intervention in his practice felt that it was simple, fast, useful and very well-received 
by his patients.  However, as time is extremely limited in the primary care visit, he 
recommended involvement of care-extenders to facilitate enrollment.  The nurse reported 
very positive reception from her patients and she felt that the device was easy to operate 
and useful as a motivational tool.  She felt that the intervention could easily be 
incorporated into her clinical practice and would “definitely” use the device for her 
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individual patient visits as well as group education sessions, were it commercially 
available. 
 
The consent and questionnaire processes represent at least half of the 10-15 minutes 
required for the intervention.  The physician reported that these steps made it difficult to 
incorporate the study into his clinical schedule.  Thus, while the device may represent a 
useful and viable intervention by itself, it does not appear feasible to ask busy primary 
care doctors to bear the burden of the paperwork associated with a larger study.  
Administration of the intervention by care-extenders may provide benefits outside of any 
derived from the heuristic itself; one study of 457 participants found that patients who 
received supplementary care from specially trained nurses had better blood pressure 
control and medical adherence behavior when compared to those who received standard 
primary care (56). 
 
Mechanistically, implementation of a larger study appears feasible.  In 2009, the VACT 
Primary Care Clinic treated 47,044 patients of which 25,474 (70 people per workday) 
were hypertensive by ICD-9 code.  An estimated 50 to 70% of such patients could be 
expected to have SBP greater than 140mmHg despite treatment (11, 56).  One person 
working for one month was able to enroll 30 subjects.  This suggests that the target of 
120 patients could be reached in a reasonable amount of time with one or two additional 
personnel trained to perform the intervention and associated informed consent.  Beyond 
simply increasing the number of people enrolling subjects in the same manner as in the 
pilot study, a number of additional points of contact may be explored. 
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Administration of the intervention in additional venues may allow for increased 
enrollment and could validate the use of the intervention by a wider group of 
professionals.  Triage or check-in areas, counseling, group sessions (for diabetics, 
hypertensives and other patients with chronic diseases), and blood drives all present such 
opportunities and typically are less time-restricted than the primary care office visit.  The 
pharmacy is another point of contact in which the patient is thinking about his/her health 
and may be amenable to participation.  Pharmacies offer the added advantages of 
trainable health professionals, less rigid scheduling than the clinic and, oftentimes, 
automated blood pressure machines for customer use. 
 
Prior inquiries conclude that multiple points of contact increase the likelihood of success 
for a given adherence intervention (14, 34).  A future study might examine whether serial 
applications of this intervention for an adherent patient provides a tangible sense of their 
progress in reaching their blood pressure goal.  Deci et al, in their elucidation of the 
principles of SDT, note that positive feedback is associated with internalization of 
external motivations (46).  There is evidence that repeated interventions and positive 
feedback encourage the process of motivational internalization and medical adherence 
(50).  Johnson and colleagues evaluated different forms of feedback on antihypertensive 
adherence, finding that regular blood pressure monitoring had the single most significant 
influence, above that of information from the physician, family or the media (23).  Such 
reinforcement may be associated with increased sense of accomplishment, competence 
and autonomous motivation.  The present intervention may serve as a possible corollary 
 55 
to routine blood pressure measurement, intended to give the patient a conscious, tangible 
manifestation of the numbers recorded in his/her chart and the progress that they 
represent. 
 
One strength of this intervention is that the degree of feedback increases with the severity 
of disease.  In informal testing, it takes several squeezes to notice a difference of 10-
20mmHg but higher differences than this are quite easily detected.  The higher a person’s 
SBP, the greater the difference in pressure that they feel upon squeezing the two bladders 
and the faster their “hypertensive” arm gets tired.  Presumably, the emotional weight and 
educational value of the intervention increases in proportion to the magnitude of the 
pressure difference experienced and thus with the severity of disease.  It seems logical to 
believe that the psychological impact, motivational utility and degree of improvement in 
outcome variables would be more pronounced for higher pressures.  The present study 
was insufficiently powered to explore this question and may provide an interesting 
avenue of exploration for a larger inquiry.  Further investigations may benefit from a 
higher blood pressure cutoff value for screening purposes as well as targeting patients 
early in the course of their disease in hopes of maximizing changes in adherence. 
 
Limitations 
All subjects were male veterans which seriously limits the generalizability of the results 
of this pilot study.  In addition, the sample size was often insufficient to establish 
statistical significance of the intra-Group outcomes and in cases where significant 
improvements in the Intervention Group were identified, significant inter-Group 
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differences with the Control were not always established.  In order for the Intervention 
Group’s mean outperformance in MMAS (the primary outcome) of 0.6 to have been 
significant the required sample size would have been 329 subjects after losses to 
followup, assuming the realized standard deviation of 1.8, power = 0.80 and p = 0.05.  
The modesty of this inquiry was necessitated by limited resources and the desire to 
minimize the disruption to the activities of the Clinic.  The exclusion of subjects with 
history of advanced vascular compromise or atherosclerosis was intended to reduce the 
chance of adverse events associated with participation in the intervention.  However, it is 
possible that this group of patients would benefit substantially from improved adherence 
to antihypertensive prescriptions and their exclusion from the study limits its relevance to 
clinical practice.  As physical effort involved in participation is quite minimal, the risk to 
these patients is likely small and a larger study should consider their inclusion. 
 
The study’s design limited its utility as a pilot.  More data on recruitment, uptake of 
intervention, patient satisfaction and acceptability should have been sought.  Because a 
convenience sample was employed, very few people decided not to participate, however 
a larger study may approach sequential patients, likely resulting in higher rates of refusal.  
Physicians recommending their patients for the study may have selected for more 
agreeable personalities which could have introduced additional confounding to the 
adherence metrics.  Nevertheless, the results of the immediate motivational impact 
question and clinician interviews suggest that patients were amenable and generally 




For practical reasons, the process of randomization and Group allocation was known to 
the enrolling co-investigator.  Due to their necessary participation in the intervention, 
subjects were also aware of their status in the study.  The effect of the former may have 
led to selection or measurement biases while the latter may have encouraged attention 
bias. 
 
The question gauging the immediate motivational impact of the session was developed by 
the investigators and had no external or predictive validation outside this study.  The 
question used the term “motivation” but it did not define this word and it did not attempt 
to parse out autonomous and controlled components.  As a result, comparability with 90-
day TSRQ responses is limited.   
 
As discussed above, index levels for self-reported adherence and medication possession 
were significantly correlated.  However, changes in these metrics were positively but not 
significantly related.  Any relationship between the two was likely weakened by the 
difference in timing between the administration of the MMAS at 90 days and the year-
long scope of the MPR.  It also appears that MMAS responses were subject to ceiling 
effect with significant overestimation of index adherence by self-report allowing little 
space for improvement ex post. 
 
The measurement of medication possession ratio presented several challenges.  The 
model was highly detailed and required manual input of several thousand datapoints.  
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Changes in medication classes or brands during the study period were not examined.  It is 
possible that such a change may produce an impact on adherence that would be 
erroneously attributed to the session.  While the model does include drug names, it does 
not consider whether medication adherence rates varied with drug class.  A prior study 
found that averaging MPR data across antihypertensive classes did not mask any class-
specific differences in adherence (87).  Data regarding non-VA medications were 
inconsistent.  In one Intervention and two Control subjects, such data was missing and 
these patients were not included in MPR calculations.  It is plausible that patients who fill 
their meds outside the VA are wealthier or have better access to the healthcare system, 
both variables found to be associated with higher adherence.  Finally, the VA pharmacy 
presents a semi-closed system in which data for most patients are readily available.  A 
larger study outside the VA system would have the added challenge of gathering MPR 
data from a variety of sources. 
 
Review of prescription records provides data on gross consumption patterns but not on 
more granular adherence phenomena: for example, if the subject is consistently missing 
his weekend doses, nighttime doses or if he misses doses sporadically.  These questions 
could have been addressed by MEMS and allowed for a richer analysis of changes in 
adherence.  Each visit is an opportunity for changes to medical plan of treatment and 
some patients have their medications changed or supplemented with new medications.  
As the index session occurred immediately following a routine primary care visit, new 
medications or new dosages were often introduced on the same day as the session.  If the 
intervention had any effect, it seems plausible that this effect would be greatest at the 
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time of the session which, in this case, coincides with new scripts being written.  This 
“white-coat adherence” would have the effect of augmenting any MPR changes than had 
the intervention occurred between medical visits (121) along with the confounding 
effects of new antihypertensives introduced at the time of the intervention. 
 
Similarly, it is often difficult to distinguish between different types of nonadherent 
behavior.  For example, two separate analyses may report 50% adherence but this can 
indicate that either 100% of patients stopped therapy halfway through the period or that 
100% of patients took half their medicine for the entire period.  A rough analysis of the 
pharmacy data indicate that the change in the number of days with no pills taken was 
inversely proportional to the change in MPR.  This suggests that changes in adherence 
were more likely to include all hypertension scripts rather than piecemeal decisions by 
the patient to improve adherence to just one or two drugs.  Furthermore, pairwise 
correlation and OLS regression analyses were limited to those subjects for whom 
complete MMAS followup was possible. 
 
There were substantial losses to followup in the blood pressure data as those without 
appointments within 15 days of followup dates were excluded from these calculations 
which reduced sample size most substantially for the 180- and 270-day comparisons.  
This problem could have been ameliorated by taking averages of blood pressure data over 
wider windows rather than discrete, periodic readings.  Lost subjects may have been 
more prone to poor adherence and their loss may have resulted in overestimation of post-




The results of this inquiry suggest that a brief educational intervention designed to 
provide a somatosensory manifestation of the patient’s disease process shows promise in 
promoting adherent behavior and clinically useful reductions in blood pressure in poorly 
controlled hypertensives.  A larger study appears feasible and is required to confirm and 
investigate the statistical significance of these results. 
 
Should further studies prove encouraging, there may be potential use for this device in 
several healthcare-associated venues.  It is simple, inexpensive, fast and noninvasive and 
thus potentially useful for primary care physicians, nurses, PAs, or pharmacists, 
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